Skip to content
2000
image of The Physiology of Semaglutide in Relation to Glucagon Like Peptide-1: A Comprehensive Review

Abstract

Semaglutide (marketed as Ozempic®), a glucagon-like peptide-1 (GLP-1) receptor agonist, has revolutionized the management of type 2 diabetes mellitus and obesity. GLP-1 plays a pivotal role in regulating glucose metabolism, appetite, and energy homeostasis through its actions on α and β pancreatic cells, gastric emptying, and the central nervous system. By augmenting insulin secretion, suppressing glucagon production, slowing gastric emptying, and promoting satiety, Semaglutide offers a multifaceted approach to maintaining glucose homeostasis and energy balance. This review delves into the intricate physiology of Semaglutide, exploring how it mimics and enhances GLP-1's natural functions, shedding light on Semaglutide’s growing role as a therapeutic powerhouse in combating metabolic disorders. Additionally, we compare the outcomes of using different GLP-1 receptor agonists besides Semaglutide, demonstrating that Semaglutide has the most potent effect. Finally, this review provides an in-depth understanding of the physiological and therapeutic potential of Semaglutide, emphasizing its critical role in modern healthcare.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdth/10.2174/0115748855404783250917112146
2025-10-08
2025-12-23

  • From This Site

    /content/journals/cdth/10.2174/0115748855404783250917112146
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Kalra S. Sahay R. A review on semaglutide: An oral glucagon-like peptide 1 receptor agonist in management of type 2 diabetes mellitus. Diabetes Ther. 2020 11 9 1965 1982 10.1007/s13300‑020‑00894‑y 32725484
    [Google Scholar]
  2. Gundapaneni S.R.C. Burri R.G. Kaku R. Mamytova A. Kondadasula P. Tagaev T. Semaglutide in obesity and type 2 diabetes management: A systematic review of clinical outcomes. Cureus 2025 17 2 78555 10.7759/cureus.78555 40062102
    [Google Scholar]
  3. Popoviciu M.S. Păduraru L. Yahya G. Metwally K. Cavalu S. Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials. Int. J. Mol. Sci. 2023 24 13 10449 10.3390/ijms241310449 37445623
    [Google Scholar]
  4. Papakonstantinou I. Tsioufis K. Katsi V. Spotlight on the mechanism of action of semaglutide. Curr. Issues Mol. Biol. 2024 46 12 14514 14541 10.3390/cimb46120872 39728000
    [Google Scholar]
  5. Nadkarni P. Chepurny O.G. Holz G.G. Regulation of glucose homeostasis by GLP-1. Prog. Mol. Biol. Transl. Sci. 2014 121 23 65 10.1016/B978‑0‑12‑800101‑1.00002‑8 24373234
    [Google Scholar]
  6. Moiz A. Filion K.B. Tsoukas M.A. Yu O.H.Y. Peters T.M. Eisenberg M.J. Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation. Am. J. Med. 2025 138 6 934 940 10.1016/j.amjmed.2025.01.021 39892489
    [Google Scholar]
  7. Decarie-Spain L. Kanoski S.E. Ghrelin and glucagon-like peptide-1: A gut-brain axis battle for food reward. Nutrients 2021 13 3 977 10.3390/nu13030977 33803053
    [Google Scholar]
  8. Holst J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007 87 4 1409 1439 10.1152/physrev.00034.2006 17928588
    [Google Scholar]
  9. Bodnaruc A.M. Prud’homme D. Blanchet R. Giroux I. Nutritional modulation of endogenous glucagon-like peptide-1 secretion: A review. Nutr. Metab. 2016 13 1 92 10.1186/s12986‑016‑0153‑3 27990172
    [Google Scholar]
  10. Davis E.M. Sandoval D.A. Glucagon‐like peptide‐1: Actions and influence on pancreatic hormone function. Compr. Physiol. 2020 10 2 577 595 10.1002/j.2040‑4603.2020.tb00123.x 32163198
    [Google Scholar]
  11. Nauck M.A. Meier J.J. Cavender M.A. Abd El Aziz M. Drucker D.J. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 2017 136 9 849 870 10.1161/CIRCULATIONAHA.117.028136 28847797
    [Google Scholar]
  12. Mathiesen D.S. Bagger J.I. Bergmann N.C. The effects of dual GLP-1/GIP receptor agonism on glucagon secretion—A review. Int. J. Mol. Sci. 2019 20 17 4092 10.3390/ijms20174092 31443356
    [Google Scholar]
  13. Ramracheya R. Chapman C. Chibalina M. GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca 2+ channels. Physiol. Rep. 2018 6 17 13852 10.14814/phy2.13852 30187652
    [Google Scholar]
  14. Drucker D.J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018 27 4 740 756 10.1016/j.cmet.2018.03.001 29617641
    [Google Scholar]
  15. Maselli D.B. Camilleri M. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv. Exp. Med. Biol. 2020 1307 171 192 10.1007/5584_2020_496 32077010
    [Google Scholar]
  16. Werner U. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying – Preclinical evidence. J. Diabetes Complications 2014 28 1 110 114 10.1016/j.jdiacomp.2013.06.003 23992745
    [Google Scholar]
  17. Marathe C.S. Rayner C.K. Jones K.L. Horowitz M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care 2013 36 5 1396 1405 10.2337/dc12‑1609 23613599
    [Google Scholar]
  18. Baggio L.L. Drucker D.J. Biology of Incretins: GLP-1 and GIP. Gastroenterology 2007 132 6 2131 2157 10.1053/j.gastro.2007.03.054 17498508
    [Google Scholar]
  19. van Bloemendaal L. ten Kulve J.S. la Fleur S.E. Ijzerman R.G. Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: Focus on the CNS. J. Endocrinol. 2014 221 1 T1 T16 10.1530/JOE‑13‑0414 24323912
    [Google Scholar]
  20. Park J.S. Kim K.S. Choi H.J. Glucagon-like peptide-1 and hypothalamic regulation of satiation: Cognitive and neural insights from human and animal studies. Diabetes Metab. J. 2025 49 3 333 347 10.4093/dmj.2025.0106 40367985
    [Google Scholar]
  21. Chen X.Y. Chen L. Yang W. Xie A.M. GLP-1 suppresses feeding behaviors and modulates neuronal electrophysiological properties in multiple brain regions. Front. Mol. Neurosci. 2021 14 793004 10.3389/fnmol.2021.793004 34975402
    [Google Scholar]
  22. Rosenstock J. Allison D. Birkenfeld A.L. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea. JAMA 2019 321 15 1466 1480 10.1001/jama.2019.2942 30903796
    [Google Scholar]
  23. Yu M. Benjamin M.M. Srinivasan S. Battle of GLP-1 delivery technologies. Adv. Drug Deliv. Rev. 2018 130 113 130 10.1016/j.addr.2018.07.009 30009885
    [Google Scholar]
  24. Lau D.C.W. Batterham R.L. le Roux C.W. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. Expert Rev. Clin. Pharmacol. 2022 15 3 251 268 10.1080/17512433.2022.2070473 35466848
    [Google Scholar]
  25. Fornes A. Huff J. Pritchard R.I. Godfrey M. Once-weekly semaglutide for weight management: A clinical review. J. Pharm. Technol. 2022 38 4 239 246 10.1177/87551225221092681 35832567
    [Google Scholar]
  26. Moiz A. Levett J.Y. Filion K.B. Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Am. J. Cardiol. 2024 222 121 130 10.1016/j.amjcard.2024.04.041 38679221
    [Google Scholar]
  27. Sorli C. Harashima S. Tsoukas G.M. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017 5 4 251 260 10.1016/S2213‑8587(17)30013‑X 28110911
    [Google Scholar]
  28. Yang X.D. Yang Y.Y. Clinical pharmacokinetics of semaglutide: A systematic review. Drug Des. Devel. Ther. 2024 18 2555 2570 10.2147/DDDT.S470826 38952487
    [Google Scholar]
  29. Jalleh R.J. Marathe C.S. Rayner C.K. Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility. Endocrinology 2024 166 1 bqae155 10.1210/endocr/bqae155 39568409
    [Google Scholar]
  30. Gabe M.B.N. Breitschaft A. Knop F.K. Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Diabetes Obes. Metab. 2024 26 10 4480 4489 10.1111/dom.15802 39082206
    [Google Scholar]
  31. Wilding J.P.H. Batterham R.L. Calanna S. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 2021 384 11 989 1002 10.1056/NEJMoa2032183 33567185
    [Google Scholar]
  32. Alorfi N.M. Algarni A.S. Clinical impact of semaglutide, a glucagon-like peptide-1 receptor agonist, on obesity management: A review. Clin. Pharmacol. 2022 14 61 67 10.2147/CPAA.S374741 35958046
    [Google Scholar]
  33. Tilinca M. Tiuca R. Niculas C. Varga A. Tilea I. Future perspectives in diabesity treatment: Semaglutide, a glucagon like peptide 1 receptor agonist (Review). Exp. Ther. Med. 2021 22 4 1167 10.3892/etm.2021.10601 34504612
    [Google Scholar]
  34. Lok K.H. Wareham N.J. Nair R.S. How C.W. Chuah L.H. Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment. Pharmacol. Res. 2022 180 106237 10.1016/j.phrs.2022.106237 35487405
    [Google Scholar]
  35. Gribble F.M. Reimann F. Enteroendocrine cells: Chemosensors in the intestinal epithelium. Annu. Rev. Physiol. 2016 78 1 277 299 10.1146/annurev‑physiol‑021115‑105439 26442437
    [Google Scholar]
  36. Santos-Hernández M. Reimann F. Gribble F.M. Cellular mechanisms of incretin hormone secretion. J. Mol. Endocrinol. 2024 72 4 230112 10.1530/JME‑23‑0112 38240302
    [Google Scholar]
  37. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004 53 9 2181 2189 10.2337/diabetes.53.9.2181 15331525
    [Google Scholar]
  38. Flint A. Raben A. Astrup A. Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 1998 101 3 515 520 10.1172/JCI990 9449682
    [Google Scholar]
  39. Drucker D.J. Nauck M.A. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006 368 9548 1696 1705 10.1016/S0140‑6736(06)69705‑5 17098089
    [Google Scholar]
  40. Bethel M.A. Patel R.A. Merrill P. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis. Lancet Diabetes Endocrinol. 2018 6 2 105 113 10.1016/S2213‑8587(17)30412‑6 29221659
    [Google Scholar]
  41. Nauck M.A. Meier J.J. Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur. J. Endocrinol. 2019 181 6 R211 R234 10.1530/EJE‑19‑0566 31600725
    [Google Scholar]
  42. Marso S.P. Bain S.C. Consoli A. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2016 375 19 1834 1844 10.1056/NEJMoa1607141 27633186
    [Google Scholar]
  43. Marso S.P. Daniels G.H. Brown-Frandsen K. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2016 375 4 311 322 10.1056/NEJMoa1603827 27295427
    [Google Scholar]
  44. Pyke C. Knudsen L.B. The glucagon-like peptide-1 receptor--or not? Endocrinology 2013 154 1 4 8 10.1210/en.2012‑2124 23267050
    [Google Scholar]
  45. Campbell J.E. Drucker D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013 17 6 819 837 10.1016/j.cmet.2013.04.008 23684623
    [Google Scholar]
  46. Wan W. Qin Q. Xie L. GLP-1R signaling and functional molecules in incretin therapy. Molecules 2023 28 2 751 10.3390/molecules28020751 36677809
    [Google Scholar]
  47. Marzook A. Tomas A. Jones B. The interplay of glucagon-like peptide-1 receptor trafficking and signalling in pancreatic beta cells. Front. Endocrinol. 2021 12 678055 10.3389/fendo.2021.678055 34040588
    [Google Scholar]
  48. Doyle M.E. Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 2007 113 3 546 593 10.1016/j.pharmthera.2006.11.007 17306374
    [Google Scholar]
  49. Secher A. Jelsing J. Baquero A.F. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J. Clin. Invest. 2014 124 10 4473 4488 10.1172/JCI75276 25202980
    [Google Scholar]
  50. van Can J. Sloth B. Jensen C.B. Flint A. Blaak E.E. Saris W.H.M. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int. J. Obes. 2014 38 6 784 793 10.1038/ijo.2013.162 23999198
    [Google Scholar]
  51. Meier J.J. Rosenstock J. Hincelin-Méry A. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: A randomized, open-label trial. Diabetes Care 2015 38 7 1263 1273 10.2337/dc14‑1984 25887358
    [Google Scholar]
  52. Knudsen L.B. Lau J. The discovery and development of liraglutide and semaglutide. Front. Endocrinol. 2019 10 155 10.3389/fendo.2019.00155 31031702
    [Google Scholar]
  53. Chaudhury A. Duvoor C. Reddy Dendi V.S. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Front. Endocrinol. 2017 8 6 10.3389/fendo.2017.00006 28167928
    [Google Scholar]
  54. Nauck M.A. Quast D.R. Wefers J. Meier J.J. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol. Metab. 2021 46 101102 10.1016/j.molmet.2020.101102 33068776
    [Google Scholar]
  55. Blonde L. Rosenstock J. Del Prato S. Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: The LixiLan-G randomized clinical trial. Diabetes Care 2019 42 11 2108 2116 10.2337/dc19‑1357 31530665
    [Google Scholar]
  56. Zheng Z. Zong Y. Ma Y. Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy. Signal Transduct. Target. Ther. 2024 9 1 234 10.1038/s41392‑024‑01931‑z 39289339
    [Google Scholar]
  57. Buse J.B. Bain S.C. Mann J.F.E. Cardiovascular risk reduction with liraglutide: An exploratory mediation analysis of the LEADER trial. Diabetes Care 2020 43 7 1546 1552 10.2337/dc19‑2251 32366578
    [Google Scholar]
  58. Ahmann A.J. Capehorn M. Charpentier G. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial. Diabetes Care 2018 41 2 258 266 10.2337/dc17‑0417 29246950
    [Google Scholar]
  59. Elsevier. (2024). Semaglutide in the management of type 2 diabetes and weight control Elsevier Health Hub https://elsevier.health/en-US/preview/semaglutide
    [Google Scholar]
  60. Pratley R.E. Aroda V.R. Catarig A. Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses. BMJ Open 2020 10 e037883 10.1136/bmjopen‑2020‑037883
    [Google Scholar]
  61. Cornell S. A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents. J. Clin. Pharm. Ther. 2020 45 Suppl. 1 17 27 10.1111/jcpt.13230 32910490
    [Google Scholar]
  62. Hankir M.K. Lutz T.A. Novel neural pathways targeted by GLP-1R agonists and bariatric surgery. Pflugers Arch. 2025 477 2 171 185 10.1007/s00424‑024‑03047‑3 39644359
    [Google Scholar]
  63. Bergmann N.C. Davies M.J. Lingvay I. Knop F.K. Semaglutide for the treatment of overweight and obesity: A review. Diabetes Obes. Metab. 2023 25 1 18 35 10.1111/dom.14863 36254579
    [Google Scholar]
  64. Sokary S. Bawadi H. Exploring beyond numeric weight loss: The metabolic effects of semaglutide. Clin. Nutr. ESPEN 2025 67 435 440 10.1016/j.clnesp.2025.03.010 40107359
    [Google Scholar]
  65. Ghusn W. De la Rosa A. Sacoto D. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw. Open 2022 5 9 2231982 10.1001/jamanetworkopen.2022.31982 36121652
    [Google Scholar]
  66. Müller T.D. Blüher M. Tschöp M.H. DiMarchi R.D. Anti-obesity drug discovery: Advances and challenges. Nat. Rev. Drug Discov. 2022 21 3 201 223 10.1038/s41573‑021‑00337‑8 34815532
    [Google Scholar]
  67. Jensen J.K. Binderup T. Grandjean C.E. Bentsen S. Ripa R.S. Kjaer A. Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis. Atherosclerosis 2022 352 88 95 10.1016/j.atherosclerosis.2022.03.032 35400496
    [Google Scholar]
  68. Gerstein H.C. Colhoun H.M. Dagenais G.R. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet 2019 394 10193 121 130 10.1016/S0140‑6736(19)31149‑3 31189511
    [Google Scholar]
  69. Ma X. Liu Z. Ilyas I. GLP-1 receptor agonists (GLP-1RAs): Cardiovascular actions and therapeutic potential. Int. J. Biol. Sci. 2021 17 8 2050 2068 10.7150/ijbs.59965 34131405
    [Google Scholar]
  70. Pratley R.E. Aroda V.R. Lingvay I. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018 6 4 275 286 10.1016/S2213‑8587(18)30024‑X 29397376
    [Google Scholar]
  71. Ji L. Dong X. Li Y. Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30‐week, double‐blind, phase 3a, randomized trial. Diabetes Obes. Metab. 2021 23 2 404 414 10.1111/dom.14232 33074557
    [Google Scholar]
  72. Singh G. Krauthamer M. Bjalme-Evans M. Wegovy (semaglutide): A new weight loss drug for chronic weight management. J. Investig. Med. 2022 70 1 5 13 10.1136/jim‑2021‑001952 34706925
    [Google Scholar]
  73. Wadden T.A. Bailey T.S. Billings L.K. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA 2021 325 14 1403 1413 10.1001/jama.2021.1831 33625476
    [Google Scholar]
  74. Gallwitz B. Giorgino F. Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide. Front. Endocrinol. 2021 12 645507 10.3389/fendo.2021.645507 34267725
    [Google Scholar]
  75. Pantanetti P. Cangelosi G. Alberti S. Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice. Front. Endocrinol. 2024 15 1394506 10.3389/fendo.2024.1394506 39015186
    [Google Scholar]
  76. Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J. Clin. Pharm. Ther. 2020 45 Suppl. 1 43 60 10.1111/jcpt.13225 32910487
    [Google Scholar]
  77. Madsbad S. Kielgast U. Asmar M. Deacon C.F. Torekov S.S. Holst J.J. An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future. Diabetes Obes. Metab. 2011 13 5 394 407 10.1111/j.1463‑1326.2011.01357.x 21208359
    [Google Scholar]
  78. ElSayed N.A. Aleppo G. Aroda V.R. Standards of Medical Care in Diabetes – 2023. Diabetes Care 2023 46 Suppl. 1 S1 S4 10.2337/dc23‑Sint
    [Google Scholar]
  79. Husain M. Birkenfeld A.L. Donsmark M. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2019 381 9 841 851 10.1056/NEJMoa1901118 31185157
    [Google Scholar]
  80. Mahapatra M.K. Karuppasamy M. Sahoo B.M. Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: A narrative Review. Pharm. Res. 2022 39 6 1233 1248 10.1007/s11095‑022‑03302‑1 35650449
    [Google Scholar]
  81. Ludvik B. Giorgino F. Jódar E. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): A randomised, open-label, parallel-group, phase 3 trial. Lancet 2021 398 10300 583 598 10.1016/S0140‑6736(21)01443‑4 34370970
    [Google Scholar]
  82. Mann J.F.E. Hansen T. Idorn T. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: A post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Lancet Diabetes Endocrinol. 2020 8 11 880 893 10.1016/S2213‑8587(20)30313‑2 32971040
    [Google Scholar]
  83. Dawed A.Y. Mari A. Brown A. Pharmacogenomics of GLP-1 receptor agonists: A genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabetes Endocrinol. 2023 11 1 33 41 10.1016/S2213‑8587(22)00340‑0 36528349
    [Google Scholar]
  84. U.S. Food and Drug Administration U.S. Food and Drug Administration. (2021) Medical review for Semaglutide (NDA 215256). Drugs@FDA https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215256Orig1s000MedR.pdf
    [Google Scholar]
/content/journals/cdth/10.2174/0115748855404783250917112146
Loading
The Physiology of Semaglutide in Relation to Glucagon Like Peptide-1: A Comprehensive Review
Bentham Science Publishers ; https://doi.org/10.2174/0115748855404783250917112146
/content/journals/cdth/10.2174/0115748855404783250917112146
/content/journals/cdth/10.2174/0115748855404783250917112146
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: GLP-1 receptor agonist ; type 2 diabetes mellitus ; gastric emptying ; metabolic disorders ; obesity ; Semaglutide

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test